0.24
+0.019(+8.59%)
Currency In USD
| Previous Close | 0.22 |
| Open | 0.26 |
| Day High | 0.26 |
| Day Low | 0.23 |
| 52-Week High | 3.96 |
| 52-Week Low | 0.12 |
| Volume | 16,160 |
| Average Volume | 5.65M |
| Market Cap | 1.91M |
| PE | -0.05 |
| EPS | -4.68 |
| Moving Average 50 Days | 0.55 |
| Moving Average 200 Days | 1.02 |
| Change | 0.02 |
If you invested $1000 in ZyVersa Therapeutics, Inc. (ZVSA) since IPO date, it would be worth $0.07 as of July 30, 2025 at a share price of $0.24. Whereas If you bought $1000 worth of ZyVersa Therapeutics, Inc. (ZVSA) shares 2 years ago, it would be worth $3.98 as of July 30, 2025 at a share price of $0.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
GlobeNewswire Inc.
Jul 21, 2025 11:55 AM GMT
WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory disease
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
GlobeNewswire Inc.
Jul 08, 2025 4:30 PM GMT
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory disease
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
GlobeNewswire Inc.
Jul 08, 2025 11:52 AM GMT
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease.D